← All trials
NCT05349097
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 8, 2022
- Primary completion
- Mar 30, 2023
- Completion date
- Jul 30, 2023
- First posted
- Apr 27, 2022
- Last posted
- Apr 27, 2022
- Enrollment
- 74
- Arms / groups
- 9 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Inmagene BiopharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.